BioMarin's VOXZOGO Hits Primary Endpoint in Phase 3 Hypochondroplasia Study
Image
San Rafael, Calif. – September 13, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) reported that its Phase 3 CANOPY-HCH-3 trial of VOXZOGO (vosoritide) met its primary endpoint in children with hypochondroplasia, with results published in NEJM Evidence and presented at the European Society for Paediatric Endocrinology 2026 Annual Meeting.